TheraRadar
Data updated: May 26, 2026

TROPICACYL (tropicamide)

Cholinergic Antagonists
Ophthalmology Approved 2000-09-29

TROPICACYL is indicated for the treatment of Mydriasis; Cycloplegia.

Source: FDA Label • EPIC PHARMA LLC
1
Indication
--
Phase 3 Trials
25
Years on Market

Details

Status
Prescription
First Approved
2000-09-29
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

Companies

Active Ingredient: TROPICAMIDE

TROPICACYL Approval History

2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 2000 to 2012
Jul 2012 SUPPL
Label · Labeling
Jun 2001 SUPPL
Mfg · Manufacturing (CMC)
Sep 2000 ORIGINAL
Update

What TROPICACYL Treats

2 indications

TROPICACYL is approved for 2 conditions since its original approval in 2000. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Mydriasis
  • Cycloplegia
Source: FDA Label

TROPICACYL Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 3 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to TROPICACYL

3 of 6

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AKPENTOLATE
CYCLOPENTOLATE HYDROCHLORIDE
2 shared
RISING
Shared indications:
MydriasisCycloplegia
CYCLOGYL
CYCLOPENTOLATE HYDROCHLORIDE
2 shared
Novartis
Shared indications:
MydriasisCycloplegia
ISOPTO ATROPINE
ATROPINE SULFATE
2 shared
Novartis
Shared indications:
MydriasisCycloplegia
📋

Clinical Trial Registry

4 trials
Trial Sponsor ID Phase Status Title
NCT03959176 results posted IRB00058366 Ph 4 completed The Effect of Brimonidine
NCT05238233 results posted 1864081 Ph 4 completed Wearing-Off Period of Pharmacological Dilation and Anisocoria
NCT05442801 Cycloplegic Refraction Ph 4 completed Cycloplegic Refraction Among Children
NCT03139708 IRB00039213 Ph 1 completed The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TROPICACYL FDA Label Details

Indications & Usage

TROPICACYL is indicated for the treatment of Mydriasis; Cycloplegia.

Track TROPICACYL with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.